Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.52 |
| ▸ | CTSD | P07339 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31666009 | 0.96 | BACE1 (0.50) | BACE1BACE2CTSDMME | |
| SCHEMBL30837136 | 0.94 | BACE1 (0.53) | BACE1BACE2CTSDENPEP | |
| SCHEMBL29880484 | 0.93 | BACE1 (0.48) | BACE1BACE2CTSDMMEENPEP | |
| SCHEMBL30814697 | 0.93 | BACE1 (0.48) | BACE1BACE2CTSDMME | |
| SCHEMBL30099600 | 0.92 | MME (0.56) | BACE1BACE2CTSDMME | |
| SCHEMBL29544149 | 0.92 | MME (0.56) | BACE1BACE2CTSDMME | |
| SCHEMBL29873713 | 0.92 | ENPEP (0.50) | BACE1ENPEP | |
| SCHEMBL29466705 | 0.91 | BACE1 (0.47) | BACE1BACE2CTSDMMEENPEP | |
| SCHEMBL31307239 | 0.91 | BACE1 (0.45) | BACE1BACE2CTSDMME | |
| SCHEMBL10439241 | 0.89 | ALDH1A1 (0.47) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025047993-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | PHAROSGEN CO., LTD. (KR) | 2025-03-06 | — | — | WO | claimed |
| US-20240091372-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-03-21 | — | — | US | claimed |
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2025-10-02 | — | — | US | disclosed |
| WO-2025047993-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | PHAROSGEN CO., LTD. (KR) | 2025-03-06 | — | — | WO | disclosed |
| US-20240091372-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091372-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | PHOSPHO1, CETP, CD79B | BACE1 3889/4885BACE2 3569/4885CTSD 2828/4885 |
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | KRAS, TP53, NRAS | BACE1 4771/4885BACE2 4729/4885CTSD 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.